JP2013516415A5 - - Google Patents

Download PDF

Info

Publication number
JP2013516415A5
JP2013516415A5 JP2012547159A JP2012547159A JP2013516415A5 JP 2013516415 A5 JP2013516415 A5 JP 2013516415A5 JP 2012547159 A JP2012547159 A JP 2012547159A JP 2012547159 A JP2012547159 A JP 2012547159A JP 2013516415 A5 JP2013516415 A5 JP 2013516415A5
Authority
JP
Japan
Prior art keywords
bis
phenylene
diyldi
pyrrolidinecarboxamide
oxazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012547159A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013516415A (ja
JP5787900B2 (ja
Filing date
Publication date
Priority claimed from US12/974,069 external-priority patent/US8362020B2/en
Application filed filed Critical
Publication of JP2013516415A publication Critical patent/JP2013516415A/ja
Publication of JP2013516415A5 publication Critical patent/JP2013516415A5/ja
Application granted granted Critical
Publication of JP5787900B2 publication Critical patent/JP5787900B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012547159A 2009-12-30 2010-12-22 C型肝炎ウィルス阻害剤 Expired - Fee Related JP5787900B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29089809P 2009-12-30 2009-12-30
US61/290,898 2009-12-30
US12/974,069 US8362020B2 (en) 2009-12-30 2010-12-21 Hepatitis C virus inhibitors
US12/974,069 2010-12-21
PCT/US2010/061855 WO2011082077A1 (en) 2009-12-30 2010-12-22 Hepatitis c virus inhibitors

Publications (3)

Publication Number Publication Date
JP2013516415A JP2013516415A (ja) 2013-05-13
JP2013516415A5 true JP2013516415A5 (enExample) 2014-01-23
JP5787900B2 JP5787900B2 (ja) 2015-09-30

Family

ID=43743509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012547159A Expired - Fee Related JP5787900B2 (ja) 2009-12-30 2010-12-22 C型肝炎ウィルス阻害剤

Country Status (5)

Country Link
US (2) US8362020B2 (enExample)
EP (1) EP2519506A1 (enExample)
JP (1) JP5787900B2 (enExample)
CN (1) CN102791693B (enExample)
WO (1) WO2011082077A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2758484A1 (en) 2009-04-15 2010-10-21 David A. Degoey Anti-viral compounds
ES2758726T3 (es) 2009-05-13 2020-05-06 Gilead Pharmasset Llc Compuestos antivirales
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
PL2628481T3 (pl) 2009-06-11 2016-08-31 Abbvie Bahamas Ltd Tripodstawione heterocykle jako inhibitory replikacji wirusa HCV zapalenia wątroby typu C
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
AU2010274001A1 (en) 2009-07-16 2012-02-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of Flavivirus infections
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011119853A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2012027712A2 (en) 2010-08-26 2012-03-01 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis c virus
CN103402996B (zh) 2011-01-04 2015-02-11 诺瓦提斯公司 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
US8552047B2 (en) * 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
EP2802608A4 (en) * 2012-01-12 2015-08-05 Univ Yale COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY E3 UBIQUITIN LIGASE
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013118097A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
ES2648962T3 (es) 2012-06-28 2018-01-09 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la vía del complemento
EP2867225B1 (en) 2012-06-28 2017-08-09 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
EP2867227B1 (en) 2012-06-28 2018-11-21 Novartis AG Complement pathway modulators and uses thereof
ES2644700T3 (es) 2012-06-28 2017-11-30 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
CN105121429B (zh) 2012-06-28 2017-12-12 诺华股份有限公司 补体途径调节剂和其用途
BR112015000578A2 (pt) 2012-07-12 2017-06-27 Novartis Ag moduladores da via do complemento e usos dos mesmos
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー 2つの抗ウイルス化合物の組合せ製剤
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN113549110B (zh) 2016-04-07 2024-08-16 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
US10889553B2 (en) 2017-12-01 2021-01-12 Nysnobio Ireland Dac Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same
CN110054574B (zh) * 2019-04-11 2021-08-20 上海吉奉生物科技有限公司 一种芴甲氧羰基-2,3-脱氢-缬氨酸的合成方法
JP7725617B2 (ja) 2021-05-21 2025-08-19 ギリアード サイエンシーズ, インコーポレイテッド ジカウイルス阻害剤としての五環式誘導体
WO2022246072A1 (en) 2021-05-21 2022-11-24 Gilead Sciences, Inc. Tetracyclic compounds for the treatment of zika virus infection

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852503A (en) 1953-12-31 1958-09-16 American Cyanamid Co 2, 5-bis (p-aminophenyl) furan azo derivatives
JP2805896B2 (ja) * 1989-10-06 1998-09-30 日本電気株式会社 電子写真感光体
US5654451B1 (en) 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
EP0679153A4 (en) 1993-01-14 1996-05-15 Magainin Pharma FINALLY MODIFIED AMINO ACIDS AND PEPTIDES.
JP4181650B2 (ja) * 1997-08-15 2008-11-19 株式会社リコー 電子写真感光体
EP1103573B1 (en) 1999-05-07 2004-09-15 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Liquid-crystal polymer
JP2000318312A (ja) * 1999-05-07 2000-11-21 Mitsui Chemicals Inc 光記録媒体
US6987184B2 (en) 2001-02-15 2006-01-17 Signal Pharmaceuticals, Llc Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2004005264A2 (en) 2002-07-05 2004-01-15 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections
HRP20050168A2 (en) * 2002-08-23 2005-10-31 Rigel Pharmaceuticals Pyridyl substituted heterocycles useful for treating or preventing hcv infection
US20050256179A1 (en) 2003-08-08 2005-11-17 Sircar Jagadish C Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
ES2348332T3 (es) 2005-09-16 2010-12-02 Arrow Therapeutics Limited Derivados de bifenilo y su uso en el tratamiento de la hepatitis c.
WO2007058384A1 (en) 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
NZ569817A (en) 2005-12-21 2011-10-28 Abbott Lab Anti-viral compounds
EP1971611B1 (en) 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
CA2653924A1 (en) 2006-05-30 2007-12-06 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
US9873667B2 (en) 2006-07-27 2018-01-23 Emisphere Technologies Inc. Arylsulfanyl compounds and compositions for delivering active agents
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
TW200831084A (en) 2006-11-21 2008-08-01 Genelabs Tech Inc Anti-viral compounds
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
EP2250163B1 (en) 2008-02-12 2012-03-28 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
BRPI0907733A2 (pt) 2008-02-12 2015-07-14 Bristol Myers Squibb Co Inibidores do vírus da hepatite c
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2010008863A (es) 2008-02-13 2010-09-07 Bristol Myers Squibb Co Imidazolil-bifenil-imidazoles como inhibidores del virus de la hepatisis c.
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
KR20110098779A (ko) 2008-12-03 2011-09-01 프레시디오 파마슈티칼스, 인코포레이티드 Hcv ns5a의 억제제
EA024853B1 (ru) 2008-12-03 2016-10-31 Пресидио Фармасьютикалс, Инк. Ингибиторы ns5a вгс
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
EP2393359A4 (en) 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
UY32462A (es) 2009-02-23 2010-09-30 Arrow Therapeutics Ltd Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
CA2753313A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
RU2544010C2 (ru) 2009-02-27 2015-03-10 Энанта Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
MX2011010084A (es) 2009-03-27 2011-10-14 Merck Sharp & Dohme Inhibidores de la replicacion del virus de la hepatitis c.
US8709999B2 (en) 2009-03-27 2014-04-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
KR20110131312A (ko) 2009-03-27 2011-12-06 프레시디오 파마슈티칼스, 인코포레이티드 융합된 고리 c형 간염 억제제
US20110237636A1 (en) 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2758484A1 (en) 2009-04-15 2010-10-21 David A. Degoey Anti-viral compounds
JP2012524761A (ja) 2009-04-24 2012-10-18 テイボテク・フアーマシユーチカルズ ジアリールエーテル類
CA2760205A1 (en) 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
ES2758726T3 (es) 2009-05-13 2020-05-06 Gilead Pharmasset Llc Compuestos antivirales
US8980920B2 (en) 2009-05-29 2015-03-17 Merck Sharp & Dohme Corp. Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8772505B2 (en) 2009-05-29 2014-07-08 Merck Sharp & Dohme Corp. Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis C
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL2628481T3 (pl) 2009-06-11 2016-08-31 Abbvie Bahamas Ltd Tripodstawione heterocykle jako inhibitory replikacji wirusa HCV zapalenia wątroby typu C
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
AU2010274001A1 (en) 2009-07-16 2012-02-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of Flavivirus infections
RU2540897C2 (ru) 2009-08-07 2015-02-10 Тиботек Фармасьютикалз Производные бис-бензимидазола в качестве ингибиторов вируса гепатита с
WO2011015657A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Phenyl ethynyl derivatives as hepatitis c virus inhibitors
RU2012112824A (ru) 2009-09-03 2013-10-10 Тиботек Фармасьютикалз Производные бис-бензимидазола
SG178952A1 (en) 2009-09-04 2012-04-27 Glaxosmithkline Llc Chemical compounds
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031934A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
WO2011050146A1 (en) 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8415482B2 (en) 2009-12-04 2013-04-09 National Health Research Institutes Proline derivatives
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
CN104530079B (zh) 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
CA2784036A1 (en) 2009-12-24 2011-06-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
WO2011091417A1 (en) 2010-01-25 2011-07-28 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011091532A1 (en) 2010-01-28 2011-08-04 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
US20120196794A1 (en) 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors

Similar Documents

Publication Publication Date Title
JP2013516415A5 (enExample)
RU2411238C2 (ru) Цис-2,4,5-триарилимидазолины и их применение в качестве противораковых лекарственных средств
JP2019077725A5 (enExample)
CN102656141B (zh) 模拟造血生长因子的小分子化合物及其用途
US9884818B2 (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
RU2406725C2 (ru) Соединения и композиции как ингибиторы протеинкиназы
JP5487214B2 (ja) キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
TWI377910B (en) Hydrazide compound and pesticidal use of the same
JP6517928B2 (ja) キナーゼ阻害剤として有用なインドールカルボキシアミド
KR102759231B1 (ko) 키나제 억제제로서의 아미노피롤로트리아진
TW201002685A (en) Heterocyclic compound and use thereof
JP2005526723A5 (enExample)
BG107959A (bg) Заместени производни на триазол диамин като киназни инхибитори
JPWO2021107023A5 (enExample)
RU2012143794A (ru) Производные n-(имидазопиримидин-7-ил)-гетероаламидов и их применение в качестве ингибиторов pde10a
JP2010533158A5 (enExample)
JP2004502642A5 (enExample)
JP2009532454A5 (enExample)
RU2016112952A (ru) Производные индола и индазола
JP2009530274A5 (enExample)
JP2010505881A5 (enExample)
RU2013138569A (ru) Антагонисты рецептора минералокортикоидов
RU2006145205A (ru) Терапевтические соединения: пиридин в качестве каркаса
RU2015103119A (ru) Антипролиферативные бензо[в]азепин-2-оны
JP2005534627A5 (enExample)